Inflammasomes in inflammatory bowel disease pathogenesis

Current Opinion in Gastroenterology

Volumn 29, Issue 4, 2013, Pages 363-369

  Hao, Ling Yang ^a   Liu, Xikui ^a   Franchi, Luigi ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

host defense; inflammasome; inflammation; innate immunity; microbiota

Indexed keywords

ANTIBIOTIC AGENT; CASPASE 11; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18; INTERLEUKIN 1BETA;

ANTIBIOTIC THERAPY; BACTERIAL FLORA; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE; CROHN DISEASE; ENTERITIS; ENZYME ACTIVATION; GASTROENTERITIS; HOST RESISTANCE; HUMAN; INNATE IMMUNITY; INTESTINE FLORA; MICROBIAL COMMUNITY; NONHUMAN; PATHOGENESIS; REVIEW; SALMONELLA ENTERICA; SHIGELLA FLEXNERI; UBIQUITINATION;

ANIMALS; BACTERIA; CARD SIGNALING ADAPTOR PROTEINS; COLITIS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INFLAMMATORY BOWEL DISEASES; MICROBIOTA;

EID: 84879911478     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32836157a4     Document Type: Review

References (75)

1. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140:805-820.
2. Keeney KM, Finlay BB. Enteric pathogen exploitation of the microbiota-generated nutrient environment of the gut. Curr Opin Microbiol 2011; 14:92-98.
3. Gill N, Wlodarska M, Finlay BB. Roadblocks in the gut: barriers to enteric infection. Cell Microbiol 2011; 13:660-669.
4. Kamada N, Nunez G. Role of the gut microbiota in the development and function of lymphoid cells. J Immunol 2013; 190:1389-1395.
5. Lee YK, Mazmanian SK. Has the microbiota played a critical role in the evolution of the adaptive immune system? Science 2010; 330:1768-1773.
6. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012; 489:231-241.
7. Robertson SJ, Girardin SE. Nod-like receptors in intestinal host defense: controlling pathogens, the microbiota, or both? Curr Opin Gastroenterol 2013; 29:15-22.
8. Bergstrom KS, Sham HP, Zarepour M, Vallance BA. Innate host responses to enteric bacterial pathogens: a balancing act between resistance and tolerance. Cell Microbiol 2012; 14:475-484.
9. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
10. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-606.
11. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104:13780-13785.
12. Franchi L, Munoz-Planillo R, Nunez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol 2012; 13:325-332.
13. Horvath GL, Schrum JE, De Nardo CM, Latz E. Intracellular sensing of microbes and danger signals by the inflammasomes. Immunol Rev 2011; 243:119-135.
14. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117:3720-3732.
15. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009; 10:241-247.
16. Bauernfeind F, Ablasser A, Bartok E, et al. Inflammasomes: current under-standing and open questions. Cell Mol Life Sci 2011; 68:765-783.
17. Kayagaki N, Warming S, Lamkanfi M, et al. Noncanonical inflammasome activation targets caspase-11. Nature 2011; 479:117-121.
18. Aachoui Y, Leaf IA, Hagar JA, et al. Caspase-11 protects against bacteria that escape the vacuole. Science 2013; 339:975-978.
19. Franchi L, Amer A, Body-Malapel M, et al. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in Salmonella-infected macrophages. Nat Immunol 2006; 7:576-582.
20. Miao EA, Alpuche-Aranda CM, Dors M, et al. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol 2006; 7:569-575.
21. Suzuki T, Franchi L, Toma C, et al. Differential regulation of caspase-1 activation, pyroptosis, and autophagy via Ipaf and ASC in Shigella-infected macrophages. PLoS Pathog 2007; 3:1082-1091.
22. Miao EA, Ernst RK, Dors M, et al. Pseudomonas aeruginosa activates caspase 1 through Ipaf. Proc Nat Acad Sci USA 2008; 105:2562-2567.
23. Amer A, Franchi L, Kanneganti TD, et al. Regulation of Legionella phagosome maturation and infection through flagellin and host Ipaf. J Biol Chem 2006; 281:35217-35223.
24. Franchi L, Stoolman J, Kanneganti TD, et al. Critical role for Ipaf in Pseudomonas aeruginosa-induced caspase-1 activation. Eur J Immunol 2007; 37:3030-3039.
25. Sun YH, Rolan HG, Tsolis RM. Injection of flagellin intothe hostcell cytosol by Salmonella enterica serotype Typhimurium. J Biol Chem 2007; 282:33897-33901.
26. Zhao Y, Yang J, Shi J, et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 2011; 477:596-600.
27. Kofoed EM, Vance RE. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 2011; 477:592-595.
28. Lightfield KL, Persson J, Trinidad NJ, et al. Differential requirementsfor NAIP5 in activation of the NLRC4 inflammasome. Infect Immun 2011; 79:1606-1614.
29. Qu Y, Misaghi S, Izrael-Tomasevic A, et al. Phosphorylation of NLRC4 is critical for inflammasome activation. Nature 2012; 490:539-542.
30. Bauernfeind FG, Horvath G, Stutz A, et al. Cutting edge: NF-kappaB activat-ing pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009; 183:787-791.
31. Franchi L, Eigenbrod T, Nunez G. Cutting edge: TNF-{alpha} mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation.J Immunol 2009; 183:792-796.
32. Bauernfeind F, Bartok E, Rieger A, et al. Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflamma-some. J Immunol 2011; 187:613-617.
33. Franchi L, Munoz-Planillo R, Reimer T, et al. Inflammasomes as microbial sensors. Eur J Immunol 2010; 40:611-615.
34. Iyer SS, Pulskens WP, Sadler JJ, et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci USA 2009; 106:20388-20393.
35. Li H, Ambade A, Re F. Cutting edge: necrosis activates the NLRP3 inflam-masome.J Immunol 2009; 183:1528-1532.
36. Kang TB, Yang SH, Toth B, et al. Caspase-8 blocks kinase RIPK3-mediated activation of the NLRP3 inflammasome. Immunity 2013; 38:27-40.
37. Netea MG, Nold-Petry CA, Nold MF, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytesand macrophages. Blood 2009; 113:2324-2335.
38. Piccini A, Carta S, Tassi S, et al. ATPis released bymonocytesstimulatedwith pathogen-sensing receptor ligands and induces IL-1beta and IL-18 secretion in an autocrine way. Proc Natl Acad Sci USA 2008; 105:8067-8072.
39. He Y, Franchi L, Nunez G. TLR agonists stimulate Nlrp3-dependent IL-1beta production independently of the purinergic P2X7 receptor in dendritic cells and invivo.J Immunol 2013; 190:334-339.
40. + for caspase-1 activation induced by intracellular and extracellular bacteria. J Biol Chem 2007; 282:18810-18818.
41. 2+and cAMP. Nature 2012; 492:123-127.
42. + inhibit cytochrome c-dependent formation of the apoptosome. J Biol Chem 2001; 276:41985-41990.
43. Wen H, Gris D, Lei Y, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011; 12:408-415.
44. Py BF, Kim MS, Vakifahmetoglu-Norberg H, Yuan J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol Cell 2013; 49:331-338.
45. Mishra BB, Rathinam VA, Martens GW, et al. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. Nat Immunol 2013; 14:52-60.
46. Ozkurede VU, Franchi L. Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes. Clin Exp Immunol 2012; 167:382-390.
47. Chen GY, Nunez G. Inflammasomes in intestinal inflammation and cancer. Gastroenterology 2011; 141:1986-1999.
48. Elinav E, Henao-Mejia J, Flavell RA. Integrative inflammasome activity in the regulation of intestinal mucosal immune responses. Mucosal Immunol 2013; 6:4-13.
49. Chen GY, Liu M, Wang F, et al. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J Immunol 2011; 186:7187-7194.
50. Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011; 145:745-757.
51. Normand S, Delanoye-Crespin A, Bressenot A, et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci USA 2011; 108:9601-9606.
52. Vladimer GI, Weng D, Paquette SW, et al. The NLRP12 inflammasome recognizes Yersiniapestis. Immunity 2012; 37:96-107.
53. Anand PK, Malireddi RK, Lukens JR, et al. NLRP6 negatively regulates innate immunity and host defence against bacterial pathogens. Nature 2012; 488:389-393.
54. Zaki MH, Vogel P, Malireddi RK, et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell 2011; 20: 649-660.
55. Rakoff-Nahoum S, Bousvaros A. Innate and adaptive immune connections in inflammatory bowel diseases. Curr Opin Gastroenterol 2010; 26:572-577.
56. Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482:179-185.
57. Ubeda C, Lipuma L, Gobourne A, et al. Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice. J Exp Med 2012; 209:1445-1456.
58. Smith PM, Garrett WS. The gut microbiota and mucosal T cells. Front Microbiol 2011; 2:1-6.
59. + dendritic cells: master regulators of tolerance? Trends Immunol 2011; 32:412-419.
60. Franchi L, Kamada N, Nakamura Y, et al. NLRC4-driven production ofIL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat Immunol 2012; 13:449-456.
61. Shaw MH, Kamada N, Kim YG, Nunez G. Microbiota-induced IL-1beta, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. J Exp Med 2012; 209:251-258.
62. Carvalho FA, Nalbantoglu I, Aitken JD, et al. Cytosolic flagellin receptor NLRC4 protects mice against mucosal and systemic challenges. Mucosal Immunol 2012; 5:288-298.
63. Broz P, Newton K, Lamkanfi M, et al. Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella. J Exp Med 2010; 207:1745-1755.
64. Lebeis SL, Powell KR, Merlin D, et al. Interleukin-1 receptorsignaling protects mice from lethal intestinal damage caused by the attaching and effacing pathogen Citrobacter rodentium. Infect Immun 2009; 77:604-614.
65. Liu Z, Zaki MH, Vogel P, et al. Role of inflammasomes in host defense against Citrobacterrodentium infection. J Biol Chem 2012; 287:16955-16964.
66. Kamada N, Hisamatsu T, Okamoto S, et al. Unique CD14 intestinal macro-phages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest 2008; 118:2269-2280.
67. Hasegawa M, Kamada N, Jiao Y, et al. Protective role of commensals against Clostridium difficile infection via an IL-1beta-mediated positive-feedback loop. J Immunol 2012; 189:3085-3091.
68. Bauer C, Loher F, Dauer M, et al. The ICE inhibitor pralnacasan prevents DSS-induced colitis in C57BL/6 mice and suppresses IP-10 mRNA but not TNF-alpha mRNA expression. Dig Dis Sci 2007; 52:1642-1652.
69. Loher F, Bauer C, Landauer N, et al. The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J Pharmacol Exp Ther 2004; 308:583-590.
70. Saitoh T, Fujita N, Jang MH, et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 2008; 456:264-268.
71. Coccia M, Harrison OJ, Schiering C, et al. IL-1beta mediateschronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. J Exp Med 2012; 209:1595-1609.
72. Kanai T, Watanabe M, Okazawa A, et al. Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. Gastro-enterology 2001; 121:875-888.
73. Ten Hove T, Corbaz A, Amitai H, et al. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. Gastroenterology 2001; 121:1372-1379.
74. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011; 140:1807-1816.
75. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007; 317: 124-127.